Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma
Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy....
Gespeichert in:
| Veröffentlicht in: | Neuropathology 2014-06, Vol.34 (3), p.268-276 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 276 |
|---|---|
| container_issue | 3 |
| container_start_page | 268 |
| container_title | Neuropathology |
| container_volume | 34 |
| creator | Miyazaki, Masaya Nishihara, Hiroshi Terasaka, Shunsuke Kobayashi, Hiroyuki Yamaguchi, Shigeru Ito, Tamio Kamoshima, Yuuta Fujimoto, Shin Kaneko, Sadao Katoh, Masahito Ishii, Nobuaki Mohri, Hiromi Tanino, Mishie Kimura, Taichi Tanaka, Shinya |
| description | Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS) ≥ 2), while 62 cases (53%) were negative (TS = 0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS ≥ 2) was a significant unfavorable prognostic factor (P |
| doi_str_mv | 10.1111/neup.12091 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1540229434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1540229434</sourcerecordid><originalsourceid>FETCH-LOGICAL-i2631-6c867dfebc79ccebae4f87274b40aa9b67d9988694278402cab01072f7bf82d93</originalsourceid><addsrcrecordid>eNqNkUFP3DAUhK2qFWwpl_6AKlIv9BDq53hj-wgUtkjswgFE1YvleF9YU8fZxgmw_74OSzn0VF9svflmLHsI-Qj0ENL6GnBYHwKjCt6QCXBOcxBSvSWTNFF5OeV8l7yP8Z5SEIrJHbLLeKGEYDAhj-dNM4R25WLf2hU2zhqf4YPxg-ldG7K2zi7LvMF-tfF3gwkuYPZtcZRtJ31nQqyxMxGzg_lsfv0lw6d1hzGOXhcyAJHZpMYx6M67tvIm3dSYD-RdbXzE_Zd9j9ycnV6ffM8vLmfnJ0cXuWNlAXlpZSmWNVZWKGuxMshrKZjgFafGqCqJSklZKs6E5JRZU1GggtWiqiVbqmKPHGxz1137e8DY68ZFi96bgO0QNUyTiyle8P9AC8Yl0GJM_fwPet8OXUgP0VCWFCRIOQZ-eqGGqsGlXneuMd1G__39BMAWeHQeN686UD32qsde9XOvenF6c_V8Sp5860mN4dOrx3S_dCkKMdW3i5k-pnNJp_SH_ln8Abo3o_s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660181884</pqid></control><display><type>article</type><title>Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Miyazaki, Masaya ; Nishihara, Hiroshi ; Terasaka, Shunsuke ; Kobayashi, Hiroyuki ; Yamaguchi, Shigeru ; Ito, Tamio ; Kamoshima, Yuuta ; Fujimoto, Shin ; Kaneko, Sadao ; Katoh, Masahito ; Ishii, Nobuaki ; Mohri, Hiromi ; Tanino, Mishie ; Kimura, Taichi ; Tanaka, Shinya</creator><creatorcontrib>Miyazaki, Masaya ; Nishihara, Hiroshi ; Terasaka, Shunsuke ; Kobayashi, Hiroyuki ; Yamaguchi, Shigeru ; Ito, Tamio ; Kamoshima, Yuuta ; Fujimoto, Shin ; Kaneko, Sadao ; Katoh, Masahito ; Ishii, Nobuaki ; Mohri, Hiromi ; Tanino, Mishie ; Kimura, Taichi ; Tanaka, Shinya</creatorcontrib><description>Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS) ≥ 2), while 62 cases (53%) were negative (TS = 0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS ≥ 2) was a significant unfavorable prognostic factor (P < 0.001) as well as resectability (P = 0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P < 0.001) and also overall patient survival (P < 0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.</description><identifier>ISSN: 0919-6544</identifier><identifier>EISSN: 1440-1789</identifier><identifier>DOI: 10.1111/neup.12091</identifier><identifier>PMID: 24397721</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - biosynthesis ; Brain Neoplasms - enzymology ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Deoxyribonucleic acid ; DNA ; Female ; Gene Expression Regulation, Neoplastic ; glioblastoma ; Glioblastoma - enzymology ; Glioblastoma - mortality ; Glioblastoma - pathology ; Humans ; immunohistochemistry ; Male ; MGMT ; Middle Aged ; Multivariate analysis ; O-Methylguanine-DNA Methyltransferase - analysis ; O-Methylguanine-DNA Methyltransferase - biosynthesis ; Survival analysis ; Survival Rate - trends ; temozolomide</subject><ispartof>Neuropathology, 2014-06, Vol.34 (3), p.268-276</ispartof><rights>2014 Japanese Society of Neuropathology</rights><rights>2014 Japanese Society of Neuropathology.</rights><rights>Copyright © 2014 Japanese Society of Neuropathology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fneup.12091$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fneup.12091$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24397721$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyazaki, Masaya</creatorcontrib><creatorcontrib>Nishihara, Hiroshi</creatorcontrib><creatorcontrib>Terasaka, Shunsuke</creatorcontrib><creatorcontrib>Kobayashi, Hiroyuki</creatorcontrib><creatorcontrib>Yamaguchi, Shigeru</creatorcontrib><creatorcontrib>Ito, Tamio</creatorcontrib><creatorcontrib>Kamoshima, Yuuta</creatorcontrib><creatorcontrib>Fujimoto, Shin</creatorcontrib><creatorcontrib>Kaneko, Sadao</creatorcontrib><creatorcontrib>Katoh, Masahito</creatorcontrib><creatorcontrib>Ishii, Nobuaki</creatorcontrib><creatorcontrib>Mohri, Hiromi</creatorcontrib><creatorcontrib>Tanino, Mishie</creatorcontrib><creatorcontrib>Kimura, Taichi</creatorcontrib><creatorcontrib>Tanaka, Shinya</creatorcontrib><title>Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma</title><title>Neuropathology</title><addtitle>Neuropathology</addtitle><description>Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS) ≥ 2), while 62 cases (53%) were negative (TS = 0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS ≥ 2) was a significant unfavorable prognostic factor (P < 0.001) as well as resectability (P = 0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P < 0.001) and also overall patient survival (P < 0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Brain Neoplasms - enzymology</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>glioblastoma</subject><subject>Glioblastoma - enzymology</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - pathology</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>Male</subject><subject>MGMT</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>O-Methylguanine-DNA Methyltransferase - analysis</subject><subject>O-Methylguanine-DNA Methyltransferase - biosynthesis</subject><subject>Survival analysis</subject><subject>Survival Rate - trends</subject><subject>temozolomide</subject><issn>0919-6544</issn><issn>1440-1789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFP3DAUhK2qFWwpl_6AKlIv9BDq53hj-wgUtkjswgFE1YvleF9YU8fZxgmw_74OSzn0VF9svflmLHsI-Qj0ENL6GnBYHwKjCt6QCXBOcxBSvSWTNFF5OeV8l7yP8Z5SEIrJHbLLeKGEYDAhj-dNM4R25WLf2hU2zhqf4YPxg-ldG7K2zi7LvMF-tfF3gwkuYPZtcZRtJ31nQqyxMxGzg_lsfv0lw6d1hzGOXhcyAJHZpMYx6M67tvIm3dSYD-RdbXzE_Zd9j9ycnV6ffM8vLmfnJ0cXuWNlAXlpZSmWNVZWKGuxMshrKZjgFafGqCqJSklZKs6E5JRZU1GggtWiqiVbqmKPHGxz1137e8DY68ZFi96bgO0QNUyTiyle8P9AC8Yl0GJM_fwPet8OXUgP0VCWFCRIOQZ-eqGGqsGlXneuMd1G__39BMAWeHQeN686UD32qsde9XOvenF6c_V8Sp5860mN4dOrx3S_dCkKMdW3i5k-pnNJp_SH_ln8Abo3o_s</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Miyazaki, Masaya</creator><creator>Nishihara, Hiroshi</creator><creator>Terasaka, Shunsuke</creator><creator>Kobayashi, Hiroyuki</creator><creator>Yamaguchi, Shigeru</creator><creator>Ito, Tamio</creator><creator>Kamoshima, Yuuta</creator><creator>Fujimoto, Shin</creator><creator>Kaneko, Sadao</creator><creator>Katoh, Masahito</creator><creator>Ishii, Nobuaki</creator><creator>Mohri, Hiromi</creator><creator>Tanino, Mishie</creator><creator>Kimura, Taichi</creator><creator>Tanaka, Shinya</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201406</creationdate><title>Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma</title><author>Miyazaki, Masaya ; Nishihara, Hiroshi ; Terasaka, Shunsuke ; Kobayashi, Hiroyuki ; Yamaguchi, Shigeru ; Ito, Tamio ; Kamoshima, Yuuta ; Fujimoto, Shin ; Kaneko, Sadao ; Katoh, Masahito ; Ishii, Nobuaki ; Mohri, Hiromi ; Tanino, Mishie ; Kimura, Taichi ; Tanaka, Shinya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i2631-6c867dfebc79ccebae4f87274b40aa9b67d9988694278402cab01072f7bf82d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Brain Neoplasms - enzymology</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>glioblastoma</topic><topic>Glioblastoma - enzymology</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - pathology</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>Male</topic><topic>MGMT</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>O-Methylguanine-DNA Methyltransferase - analysis</topic><topic>O-Methylguanine-DNA Methyltransferase - biosynthesis</topic><topic>Survival analysis</topic><topic>Survival Rate - trends</topic><topic>temozolomide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyazaki, Masaya</creatorcontrib><creatorcontrib>Nishihara, Hiroshi</creatorcontrib><creatorcontrib>Terasaka, Shunsuke</creatorcontrib><creatorcontrib>Kobayashi, Hiroyuki</creatorcontrib><creatorcontrib>Yamaguchi, Shigeru</creatorcontrib><creatorcontrib>Ito, Tamio</creatorcontrib><creatorcontrib>Kamoshima, Yuuta</creatorcontrib><creatorcontrib>Fujimoto, Shin</creatorcontrib><creatorcontrib>Kaneko, Sadao</creatorcontrib><creatorcontrib>Katoh, Masahito</creatorcontrib><creatorcontrib>Ishii, Nobuaki</creatorcontrib><creatorcontrib>Mohri, Hiromi</creatorcontrib><creatorcontrib>Tanino, Mishie</creatorcontrib><creatorcontrib>Kimura, Taichi</creatorcontrib><creatorcontrib>Tanaka, Shinya</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyazaki, Masaya</au><au>Nishihara, Hiroshi</au><au>Terasaka, Shunsuke</au><au>Kobayashi, Hiroyuki</au><au>Yamaguchi, Shigeru</au><au>Ito, Tamio</au><au>Kamoshima, Yuuta</au><au>Fujimoto, Shin</au><au>Kaneko, Sadao</au><au>Katoh, Masahito</au><au>Ishii, Nobuaki</au><au>Mohri, Hiromi</au><au>Tanino, Mishie</au><au>Kimura, Taichi</au><au>Tanaka, Shinya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma</atitle><jtitle>Neuropathology</jtitle><addtitle>Neuropathology</addtitle><date>2014-06</date><risdate>2014</risdate><volume>34</volume><issue>3</issue><spage>268</spage><epage>276</epage><pages>268-276</pages><issn>0919-6544</issn><eissn>1440-1789</eissn><abstract>Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS) ≥ 2), while 62 cases (53%) were negative (TS = 0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS ≥ 2) was a significant unfavorable prognostic factor (P < 0.001) as well as resectability (P = 0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P < 0.001) and also overall patient survival (P < 0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>24397721</pmid><doi>10.1111/neup.12091</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-6544 |
| ispartof | Neuropathology, 2014-06, Vol.34 (3), p.268-276 |
| issn | 0919-6544 1440-1789 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1540229434 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - biosynthesis Brain Neoplasms - enzymology Brain Neoplasms - mortality Brain Neoplasms - pathology Deoxyribonucleic acid DNA Female Gene Expression Regulation, Neoplastic glioblastoma Glioblastoma - enzymology Glioblastoma - mortality Glioblastoma - pathology Humans immunohistochemistry Male MGMT Middle Aged Multivariate analysis O-Methylguanine-DNA Methyltransferase - analysis O-Methylguanine-DNA Methyltransferase - biosynthesis Survival analysis Survival Rate - trends temozolomide |
| title | Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A00%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20evaluation%20of%20O6-methylguanine%20DNA%20methyltransferase%20(MGMT)%20expression%20in%20117%20cases%20of%20glioblastoma&rft.jtitle=Neuropathology&rft.au=Miyazaki,%20Masaya&rft.date=2014-06&rft.volume=34&rft.issue=3&rft.spage=268&rft.epage=276&rft.pages=268-276&rft.issn=0919-6544&rft.eissn=1440-1789&rft_id=info:doi/10.1111/neup.12091&rft_dat=%3Cproquest_pubme%3E1540229434%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1660181884&rft_id=info:pmid/24397721&rfr_iscdi=true |